The CJC-1295 and Ipamorelin combination is among the most researched growth hormone secretagogue stacks in preclinical peptide science. Researchers looking to buy CJC-1295 Ipamorelin in a complementary stack will find that these two peptides act through distinct but synergistic GH-releasing mechanisms, making their co-administration one of the most studied GH secretagogue protocols in animal and cell models. EdgeChems supplies both compounds individually and as a pre-formulated CJC-1295 Ipamorelin Blend for researchers investigating combined GH axis stimulation.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), the hypothalamic peptide that stimulates pituitary somatotroph cells to secrete GH. The native GHRH(1-44) has a very short plasma half-life (minutes) due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 was engineered to resist this degradation through DAC (Drug Affinity Complex) technology and strategic amino acid substitutions.
EdgeChems offers two forms:
- CJC-1295 No DAC (MOD GRF 1-29) — A shorter-acting GHRH analogue without the DAC albumin-binding moiety. This form produces more pulsatile GH release patterns relevant to physiological GH secretion studies.
- CJC-1295 With DAC — The full DAC-conjugated version, which binds to plasma albumin to extend half-life significantly. Research models using CJC-1295 DAC typically examine sustained GH elevation vs. pulsatile patterns.
What Is Ipamorelin?
Ipamorelin is a selective Growth Hormone Secretagogue Receptor (GHSR-1a) agonist — a ghrelin mimetic that stimulates GH release from pituitary somatotrophs through the ghrelin receptor pathway. Unlike other GHSR agonists such as GHRP-6 or GHRP-2, Ipamorelin is highly selective for GH release with minimal co-stimulation of ACTH (adrenocorticotropic hormone) or cortisol — a property that makes it valuable for research models where isolating GH axis effects without adrenal axis interference is important.
Ipamorelin’s selectivity, clean side-effect profile in animal studies, and well-characterised pharmacokinetics have made it one of the most studied GHSR agonists in both academic and pharmaceutical research settings. Buy Ipamorelin for sale from EdgeChems as a research-grade compound at ≥98% HPLC-verified purity.
Why Combine CJC-1295 and Ipamorelin?
CJC-1295 and Ipamorelin act through entirely different receptors to stimulate GH release — CJC-1295 via the GHRH receptor (GHRHR) and Ipamorelin via the ghrelin receptor (GHSR-1a). In research models, simultaneous activation of both pathways produces synergistic GH release that is significantly greater than either compound alone. This synergism occurs because:
- GHRH (via CJC-1295) amplifies somatotroph responsiveness by increasing intracellular cAMP
- Ghrelin agonism (via Ipamorelin) activates Gq-protein signalling pathways that mobilise intracellular calcium in somatotrophs
- The two pathways converge at the level of VDCC (voltage-dependent calcium channel) activation, producing a supraadditive GH secretory pulse
In animal studies, the combination consistently produces GH pulses of greater amplitude and duration than either compound alone — making it a standard protocol in GH axis research.
CJC-1295 No DAC vs With DAC: Research Considerations
The choice between CJC-1295 No DAC and CJC-1295 With DAC depends on the research objective:
- No DAC (MOD GRF 1-29): Produces sharp GH pulses resembling physiological GHRH pulsatility. Typically used in research studying pulsatile GH secretion, IGF-1 dynamics, and tissue responses to natural-pattern GH release.
- With DAC: Produces sustained GH elevation over 1-2 weeks per administration in animal models. Used in research examining chronic GH axis stimulation, body composition models, and long-duration GH elevation studies.
Sermorelin: A Related GHRH Analogue
Researchers studying GHRH analogues may also investigate Sermorelin, the synthetic GHRH(1-29) fragment. Sermorelin was historically used in clinical diagnostic settings (now discontinued) to assess GH secretory capacity, and remains a reference compound in academic GHRH research. Its shorter sequence and different degradation profile distinguish it from CJC-1295 in research protocol design.
Product Specifications
- CJC-1295 No DAC: ≥98% purity, HPLC verified — order here
- CJC-1295 With DAC: ≥98% purity, HPLC verified — order here
- Ipamorelin: ≥98% purity, HPLC verified — order here
- CJC-1295 + Ipamorelin Blend: Pre-formulated dual peptide — order here
- Storage: -20°C, protected from light and moisture
Research Applications Summary
- GH axis stimulation and pulsatile secretion studies
- IGF-1 modulation research in animal models
- Body composition and metabolic research using GH secretagogues
- GHRH receptor and ghrelin receptor pharmacology studies
- Synergistic GH secretagogue combination research
For research purposes only. Not intended for human or veterinary use. All information is presented for scientific reference.